HbA1c and cardiovascular risk score identify people who may benefit from preventive interventions: a 7 year follow-up of a high-risk screening programme for diabetes in primary care (ADDITION), Denmark
Open Access
- 22 February 2011
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 54 (6) , 1318-1326
Abstract
The measurement of HbA1c is suggested as a diagnostic test for diabetes. Screening for diabetes also identifies individuals with elevated cardiovascular risk but who are free of diabetes. This study aims to assess whether screening by HbA1c or glucose measures alone, or in combination with a cardiovascular risk assessment, identifies people who may benefit from preventive interventions, i.e. people with screen detected diabetes and people belonging to groups with excess mortality, during a median follow-up of 7 years. A population-based, stepwise high-risk screening programme was performed in 193 family practices from 2001 to 2006. Individuals aged between 40 and 69 years (N = 163,185) were sent a diabetes risk questionnaire. Of these, 20,916 people at risk of diabetes were stratified by glucose measures (normal glucose tolerance [NGT], impaired fasting glucose [IFG], impaired glucose tolerance [IGT] and diabetes), HbA1c (1c ≥ 6.0% identified 96.7% (95% CI 96.3–97.0%), compared with 97.6% (95%CI 97.2–97.9%) in combination with glucose measures. Glucose measures or HbA1c alone identified 26.1% (95% CI 25.2–27.0%) and 19.8% (95% CI 19.0–20.6%), respectively. In a population-based high risk screening programme in primary care, HbA1c ≥ 6.0% combined with an elevated cardiovascular risk assessment (SCORE ≥ 5) can feasibly be used to identify those who may benefit from preventive lifestyle intervention and/or polypharmacy. ClinicalTrials.gov NCT 00237549. The study received unrestricted grants from Novo Nordisk, Novo Nordisk Scandinavia, Astra Denmark, Pfizer Denmark, GlaxoSmithKline Pharma Denmark, Servier Denmark and HemoCue Denmark.Keywords
This publication has 22 references indexed in Scilit:
- Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysisThe Lancet, 2010
- General practitioners’ adherence to guidelines on management of dyslipidaemia: ADDITION-DenmarkScandinavian Journal of Primary Health Care, 2009
- The Impact of Prevention on Reducing the Burden of Cardiovascular DiseaseCirculation, 2008
- Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION studyDiabetologia, 2008
- Effect of a Multifactorial Intervention on Mortality in Type 2 DiabetesNew England Journal of Medicine, 2008
- What determines the cost-effectiveness of diabetes screening?Diabetologia, 2006
- Population-based stepwise screening for unrecognised Type 2 diabetes is ineffective in general practice despite reliable algorithmsDiabetologia, 2004
- Prevalences of Diabetes and Impaired Glucose Regulation in a Danish PopulationDiabetes Care, 2003
- Diabetic Patients Detected by Population-Based Stepwise Screening Already Have a Diabetic Cardiovascular Risk ProfileDiabetes Care, 2002
- Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projectionsDiabetes Care, 1998